secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023528
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside reports Q3 net loss of $7.8M; OASIS trial shows positive durability for CLS-AX
--------------------------------------------------------------------------------

- Q3 2022 net loss of $7.8M ($0.13/share) vs $4.9M loss in Q3 2021; revenue fell to $0.3M from $3.1M.
- OASIS Phase 1/2a met primary safety endpoint; no serious adverse events in 27 wet AMD patients.
- Cohorts 3/4: 88% injection-free to Month 5, 75% to Month 6; >90% reduction in treatment burden.
- Company expects to initiate Phase 2 trial for CLS-AX in wet AMD in Q1 2023.
- Entered royalty interest sale with HealthCare Royalty for up to $65M non-dilutive funding; cash $53.4M, runway into 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022023528/0000950170-22-023528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022023528/clsd-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer